GlassScriptPhysician profile
Phildrich Teh
NPI 1265895114
$7,807.66
in general payments reported to CMS, 2019-2025
32 companies · $2,774 in 2025
The $2,774 reported for 2025 was more than what 75% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $360 · 2021: $618 · 2022: $630 · 2023: $861 · 2024: $2,178 · 2025: $2,774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,713 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,712.96 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,780.97 | 2019-2025 | Evenity, Otezla, Krystexxa |
| Abbvie INC. | $986.85 | 2020-2025 | Rinvoq |
| Glaxosmithkline, LLC. | $836.18 | 2019-2025 | Benlysta |
| Ucb, INC. | $648.56 | 2022-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $588.96 | 2024-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $490.86 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $434.19 | 2020-2024 | Ofev, Cyltezo |
| Astrazeneca Pharmaceuticals LP | $316.15 | 2023-2025 | Saphnelo |
| Pfizer INC. | $302.72 | 2019-2025 | |
| Genentech USA, INC. | $225.85 | 2019-2025 | Actemra, Gazyva |
| Lilly USA, LLC | $213.28 | 2023-2025 | Taltz, Olumiant, Zepbound |
| Actelion Pharmaceuticals US, INC. | $131.71 | 2023-2025 | Opsumit, Uptravi |
| Mallinckrodt Hospital Products INC. | $92.78 | 2024-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $84.69 | 2024 | Strensiq, Ultomiris |
| Horizon Therapeutics Plc | $83.08 | 2022-2023 | Krystexxa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $78.46 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $64.64 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $64.47 | 2022-2023 | Seglentis |
| Radius Health, INC. | $57.04 | 2023 | Tymlos |
| Ferring Pharmaceuticals INC. | $53.32 | 2019-2024 | Euflexxa |
| Organon LLC | $39.44 | 2025 | Hadlima, Renflexis |
| Kyowa Kirin, INC. | $29.24 | 2024 | |
| Octapharma USA, INC. | $25.51 | 2024 | Octagam Immune Globulin (Human) |
| E.R. Squibb & Sons, L.L.C. | $24.00 | 2020 | |
| Aurinia Pharma U.S., INC. | $23.66 | 2024 | Lupkynis |
| Regeneron Healthcare Solutions, INC. | $23.47 | 2022 | |
| Hikma Pharmaceuticals USA | $20.28 | 2019 | |
| Tersera Therapeutics LLC | $19.09 | 2025 | Quzyttir |
| Sobi, INC | $19.07 | 2025 | |
| Scilex Pharmaceuticals INC. | $17.89 | 2025 | |
| Genzyme Corporation | $16.17 | 2025 | |
| Tonix Medicines, INC. | $15.08 | 2025 | Tonmya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phildrich Teh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.